Advanced Renal Pathophysiology
Nephrotic & Nephritic Syndromes: The Why of the Why
A deep exploration of glomerular pathophysiology—understanding why the filtration barrier fails and how this manifests as distinct clinical syndromes.
Foundational Principles: Two Syndromes, One Structure
Nephrotic and nephritic syndromes represent two fundamentally different modes of glomerular injury. Understanding why requires understanding what the glomerulus does and how it can fail.
The Central Question: Why Two Different Syndromes?
The glomerulus has one job: selective filtration. It must filter 180 liters of plasma daily while retaining proteins and blood cells. When this barrier fails, it can fail in two fundamentally different ways—and this determines whether you see nephrotic or nephritic syndrome.
The barrier becomes "leaky" to proteins
Massive proteinuria (>3.5 g/day)
Hypoalbuminemia
Edema
Hyperlipidemia
Lipiduria
Primary defect: Podocyte/charge barrier injury
The barrier becomes "inflamed" with cellular invasion
Hematuria (RBC casts)
Mild-moderate proteinuria
Hypertension
Oliguria
Azotemia (↑BUN/Cr)
Primary defect: Inflammatory damage to GBM/endothelium
Why do these two syndromes look so different clinically?
Because they represent injury to different components of the filtration barrier. Nephrotic = podocyte/charge barrier damage (proteins leak). Nephritic = endothelial/GBM inflammatory damage (blood leaks, GFR drops).
Why does podocyte injury cause protein loss but not blood loss?
Podocytes maintain the size-selective and charge-selective barrier through their slit diaphragms. When podocytes are injured, proteins (especially albumin) slip through, but the basement membrane remains intact—RBCs are too large to pass through GBM alone.
Why does inflammatory damage cause hematuria?
Inflammation damages the GBM and endothelium, creating actual breaks in the barrier. These breaks allow RBCs to escape into Bowman's space. Inflammatory mediators also recruit neutrophils that release proteases, further degrading the matrix.
Why does nephritic syndrome cause hypertension while nephrotic causes edema?
Nephritic: ↓GFR → salt/water retention → volume expansion → hypertension. The kidneys cannot excrete the normal sodium load. Nephrotic: albumin loss → ↓oncotic pressure → fluid shifts to interstitium → edema with intravascular depletion → RAAS activation → more sodium retention.
Why can some diseases cause features of both syndromes?
Because some diseases injure multiple components simultaneously. Membranoproliferative GN damages both podocytes AND causes immune complex deposition with inflammation. Lupus nephritis can present as pure nephrotic, pure nephritic, or mixed—depending on the predominant histological class.
Understanding the Spectrum
Rather than thinking of nephrotic and nephritic as binary categories, think of them as opposite ends of a spectrum determined by which component of the filtration barrier is most affected:
The Injury Spectrum
Pure Nephrotic (Podocyte-predominant): Minimal Change Disease, FSGS, Membranous Nephropathy. The podocyte or its slit diaphragm is the primary target. GBM remains intact. No inflammation. Massive proteinuria, minimal hematuria.
Mixed Features: Membranoproliferative GN, Lupus Nephritis (Class III-V), Diabetic Nephropathy (advanced). Both podocyte dysfunction AND inflammatory/proliferative changes. Significant proteinuria WITH active sediment.
Pure Nephritic (Inflammatory-predominant): Post-streptococcal GN, IgA Nephropathy (during flares), ANCA vasculitis, Anti-GBM disease. Inflammation dominates. RBC casts, ↓GFR, hypertension. Proteinuria is present but not massive.
Clinical Pearl
When you see a patient with glomerular disease, ask: "Is this primarily protein leaking (nephrotic), blood leaking (nephritic), or both?" This simple framework guides your differential and workup. The presence of RBC casts is pathognomonic of glomerular inflammation—you cannot have nephritic syndrome without glomerular hematuria.
Evidence Base
KDIGO 2021 Clinical Practice Guideline for Glomerulonephritis • Floege J, Amann K. Primary glomerulonephritides. Lancet 2016 • Sethi S, et al. Mayo Clinic/Renal Pathology Society Consensus on Pathologic Classification. Kidney Int 2020
The Glomerular Filtration Barrier: Anatomy of Selectivity
To understand why the barrier fails, you must first understand how it works. The glomerular filtration barrier is a marvel of biological engineering—three layers working in concert.
The Three Layers of the Filtration Barrier
Fenestrated Endothelium
Glomerular endothelial cells contain fenestrations (70-100 nm pores) that allow free passage of water and small solutes while blocking blood cells. These fenestrations are covered by a glycocalyx—a negatively charged carbohydrate layer that repels albumin (also negatively charged). The endothelium is the first line of defense against blood cell passage and contributes to charge selectivity.
Glomerular Basement Membrane (GBM)
A 300-350 nm thick matrix of type IV collagen, laminin, nidogen, and proteoglycans (mainly heparan sulfate). The GBM provides SIZE selectivity—molecules >70 kDa are largely excluded. It also contributes to CHARGE selectivity through its anionic heparan sulfate proteoglycans. The GBM has three layers: lamina rara interna, lamina densa, and lamina rara externa.
Podocytes and Slit Diaphragm
Podocytes are specialized epithelial cells with foot processes that interdigitate, connected by the slit diaphragm—a zipper-like structure only 40 nm wide. The slit diaphragm is composed of nephrin, podocin, CD2AP, and other proteins. This is the FINAL barrier—molecules that pass through endothelium and GBM must still navigate the slit diaphragm. Podocyte injury is the primary cause of nephrotic syndrome.
Molecular Components of the Slit Diaphragm
Nephrin: Transmembrane protein encoded by NPHS1 gene. Forms the backbone of the slit diaphragm by interacting with nephrin molecules from adjacent foot processes. Mutations cause congenital nephrotic syndrome (Finnish type).
Podocin: Encoded by NPHS2. Anchors nephrin to the podocyte cytoskeleton and lipid rafts. Mutations cause steroid-resistant nephrotic syndrome.
CD2AP: Links the slit diaphragm to the actin cytoskeleton. Essential for maintaining foot process architecture.
TRPC6: Calcium channel in podocytes. Gain-of-function mutations cause FSGS by increasing calcium influx and podocyte injury.
How Selectivity Works: Size vs. Charge
Why doesn't albumin (66 kDa) pass through if the size cutoff is ~70 kDa?
Because CHARGE matters as much as size. Albumin is negatively charged at physiological pH. The GBM and podocyte glycocalyx are also negatively charged (anionic). Like charges repel—albumin is electrostatically excluded even though it's small enough to potentially pass. This is why charge barrier loss causes massive proteinuria.
Why are RBCs (7-8 μm) retained when fenestrations are only 70-100 nm?
RBCs are simply too large—by orders of magnitude. Even deformed, they cannot squeeze through 100 nm fenestrations. When you see hematuria of glomerular origin, it means there are actual BREAKS in the barrier, not just increased permeability. These breaks are typically caused by inflammation or necrotizing injury.
Why do podocytes, once injured, have trouble recovering?
Podocytes are terminally differentiated cells—they cannot divide. When podocytes are lost, they cannot be replaced by proliferation. The remaining podocytes must hypertrophy to cover the exposed GBM, but this is limited. Once podocyte density falls below a critical threshold, ongoing protein leak becomes self-perpetuating regardless of the initial insult.
Why does proteinuria itself cause more kidney damage?
Proteins in the tubular lumen are toxic to tubular epithelial cells. Tubular cells attempt to reabsorb filtered proteins via megalin/cubilin receptors, but this overwhelms their capacity. Protein reabsorption triggers inflammatory pathways (NF-κB activation), oxidative stress, and TGF-β release, leading to tubulointerstitial fibrosis—the final common pathway of CKD progression.
Why does angiotensin II worsen proteinuria?
Angiotensin II preferentially constricts the efferent arteriole, increasing intraglomerular pressure and filtration fraction. Higher pressure forces more protein through the damaged barrier. This is why ACE inhibitors/ARBs reduce proteinuria independent of blood pressure—they reduce intraglomerular pressure by dilating the efferent arteriole.
The Supporting Cast: Mesangial Cells
Mesangial cells occupy the central stalk of the glomerulus, providing structural support and regulating glomerular filtration. They are not part of the filtration barrier but are critical in glomerular disease:
Mesangial Cell Functions
Structural Support: Mesangial matrix anchors capillary loops. Loss of mesangial integrity causes capillary loop collapse.
Phagocytosis: Mesangial cells clear trapped immune complexes and debris from the GBM. Overwhelmed mesangial cells expand and proliferate.
Contractile Function: Mesangial cells contain actin and can contract, regulating glomerular blood flow and filtration surface area.
In Disease: Mesangial proliferation is a hallmark of IgA nephropathy and lupus nephritis. Mesangial expansion occurs in diabetic nephropathy. Immune complex deposition in the mesangium triggers inflammation and proliferation.
Clinical Correlation
Light microscopy findings in glomerular disease reflect which cells/structures are affected:
• Mesangial proliferation → IgA nephropathy, lupus, infection-related GN
• Endocapillary proliferation → Post-streptococcal GN, lupus
• Crescent formation → Rapidly progressive GN (ANCA, anti-GBM, severe lupus)
• GBM thickening → Membranous nephropathy, diabetic nephropathy
• Segmental sclerosis → FSGS
• Normal appearance → Minimal change disease (requires electron microscopy)
Evidence Base
Tryggvason K, Wartiovaara J. How does the kidney filter plasma? Physiology 2005 • Pavenstädt H, et al. Cell biology of the glomerular podocyte. Physiol Rev 2003 • Haraldsson B, Nyström J. The glomerular endothelium: new insights on function and structure. Curr Opin Nephrol Hypertens 2012
Nephrotic Syndrome: The Pathophysiology of Protein Loss
Nephrotic syndrome is defined by massive proteinuria (>3.5 g/day), hypoalbuminemia, edema, and hyperlipidemia. Understanding why these features occur together reveals the integrated pathophysiology.
Podocyte Injury: The Root Cause
In nephrotic syndrome, the fundamental problem is loss of the charge barrier and/or structural integrity of the slit diaphragm. The podocyte is the common final target, whether injured by immune mechanisms, genetic mutations, or toxins.
Why does podocyte injury cause massive proteinuria?
The slit diaphragm is the final barrier to protein passage. When it's disrupted—whether by foot process effacement, nephrin downregulation, or direct podocyte loss—albumin and other proteins flood through. The GBM alone cannot prevent albumin passage; it needs intact podocytes.
What is "foot process effacement" and why does it matter?
Foot process effacement is the flattening and fusion of podocyte foot processes, visible on electron microscopy. It represents podocyte injury and cytoskeletal reorganization. The interdigitating foot processes create the slit diaphragm—when they efface, the slits widen or disappear, losing filtration selectivity. Effacement is the morphological hallmark of all nephrotic diseases.
Why is effacement reversible in minimal change disease but permanent in FSGS?
In MCD, the injury is functional—podocytes efface in response to circulating factors (likely T-cell derived cytokines) but can recover when the factor is removed (steroids suppress the immune response). In FSGS, podocytes are actually lost (detached from GBM, undergo apoptosis). Since podocytes cannot regenerate, the loss is permanent and the exposed GBM scleroses.
Why is there minimal hematuria in pure nephrotic syndrome?
Because the GBM remains intact. The barrier is "leaky" to proteins but not "broken." RBCs are far too large to pass through increased permeability—they require actual structural breaks. When you see significant hematuria with nephrotic-range proteinuria, suspect a process with inflammatory component (MPGN, lupus).
Why do some patients become steroid-resistant?
If the underlying cause is genetic (mutations in NPHS1, NPHS2, TRPC6, etc.), steroids cannot correct a structural protein deficiency. If the cause is FSGS with significant podocyte loss, the damage is irreversible. Steroid resistance should prompt genetic testing and kidney biopsy if not already done.
The Nephrotic Cascade: From Proteinuria to Complications
Proteinuria → Hypoalbuminemia
Albumin (66 kDa, negatively charged) is the protein most affected by charge barrier loss. The liver attempts to compensate by increasing albumin synthesis, but cannot keep pace with urinary losses. When losses exceed synthetic capacity, serum albumin falls. Albumin <3 g/dL is typical; severe cases may drop to <1 g/dL.
Hypoalbuminemia → Edema (Underfill Theory)
Low albumin → ↓plasma oncotic pressure → fluid shifts from intravascular space to interstitium → edema. The intravascular volume depletion triggers RAAS activation → sodium retention → more edema. This "underfill" mechanism explains why severe hypoalbuminemia causes massive anasarca.
Alternative: Primary Sodium Retention (Overfill Theory)
Some nephrotic patients have normal or expanded intravascular volume, suggesting primary renal sodium retention independent of albumin. The collecting duct ENaC channel is activated by proteases in nephrotic urine (plasmin, filtered due to proteinuria), causing sodium retention. Both mechanisms likely contribute in different patients.
Hyperlipidemia: The Hepatic Response
Why does protein loss cause lipid elevation? The liver responds to low oncotic pressure with nonspecific increase in protein synthesis—including apolipoproteins. Additionally, lipoprotein lipase activity is reduced (possibly due to loss of activating cofactors in urine), impairing lipid catabolism. The result: elevated LDL, VLDL, and lipoprotein(a); low HDL.
Lipiduria: Oval Fat Bodies
Filtered lipoproteins are taken up by tubular epithelial cells. When these cells slough, they appear in urine as "oval fat bodies"—cells containing cholesterol esters that show "Maltese cross" pattern under polarized light. Lipiduria is pathognomonic of nephrotic syndrome.
The Integrated View
All nephrotic features stem from one defect: podocyte injury causing massive protein loss. Hypoalbuminemia → edema. Hepatic compensation → hyperlipidemia. The constellation of findings makes sense when you trace each back to the slit diaphragm.
Hypercoagulability: Why Nephrotic Patients Clot
Nephrotic syndrome carries a 10-40% risk of venous thromboembolism. Understanding why requires recognizing that the kidney doesn't just lose albumin—it loses anticoagulant proteins too.
Why are nephrotic patients hypercoagulable?
Multiple converging mechanisms: (1) Loss of antithrombin III in urine (AT-III is similar size to albumin). (2) Loss of protein S. (3) Increased hepatic synthesis of procoagulant factors (fibrinogen, factors V, VII, VIII). (4) Increased platelet aggregability. (5) Hyperviscosity from hyperlipidemia.
Why is antithrombin III loss so important?
AT-III is the primary inhibitor of thrombin and factor Xa—the key enzymes in the coagulation cascade. Heparin works by potentiating AT-III. When AT-III is depleted, there's unopposed thrombin generation. This is why prophylactic anticoagulation is considered when albumin <2-2.5 g/dL.
Why is renal vein thrombosis classically associated with membranous nephropathy?
Membranous nephropathy has the highest risk of thrombosis among nephrotic diseases (up to 37%). It tends to cause the most severe and persistent hypoalbuminemia. Additionally, some propose that the underlying disease (autoantibodies, especially anti-PLA2R) may have direct prothrombotic effects. Renal vein thrombosis can cause acute flank pain and hematuria, or be clinically silent.
Thrombosis Risk Stratification
Highest Risk: Membranous nephropathy, albumin <2 g/dL, immobilization, concurrent malignancy
Consider prophylactic anticoagulation when: Serum albumin <2.0-2.5 g/dL, especially in membranous nephropathy. Aspirin may be reasonable for lower-risk patients. DOACs are increasingly used over warfarin.
DVT/PE symptoms: Low threshold for imaging. Standard anticoagulation indicated if confirmed.
Evidence Base
Kodner C. Diagnosis and Management of Nephrotic Syndrome in Adults. AFP 2016 • Kerlin BA, et al. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. CJASN 2012 • KDIGO 2021 GN Guidelines
Nephritic Syndrome: The Pathophysiology of Glomerular Inflammation
Nephritic syndrome represents inflammatory injury to the glomerulus. The defining feature is glomerular hematuria (RBC casts), reflecting actual breaks in the filtration barrier. Understanding the inflammatory mechanisms reveals why GFR falls and blood pressure rises.
Immune-Mediated Glomerular Injury
Nephritic syndrome is almost always immune-mediated. The glomerulus can be attacked by three main immune mechanisms, each with distinct pathological patterns:
Autoantibodies target the α3 chain of type IV collagen in the GBM. Since collagen is distributed evenly along the GBM, immunofluorescence shows smooth, linear IgG staining.
Disease: Goodpasture syndrome (anti-GBM disease). The same antigen is present in alveolar basement membrane—hence pulmonary-renal syndrome with hemoptysis.
Why it's so severe: Direct attack on structural GBM protein causes rapid destruction. Without treatment, patients progress to ESRD in weeks. Plasmapheresis removes circulating antibodies; immunosuppression prevents new antibody formation.
Circulating immune complexes deposit in glomeruli, OR antibodies form against antigens already "planted" in the glomerulus. Deposition is patchy → granular ("lumpy-bumpy") immunofluorescence.
Diseases: Post-streptococcal GN, lupus nephritis, IgA nephropathy, membranoproliferative GN, hepatitis-associated GN, endocarditis-associated GN.
Where complexes deposit determines histology:
• Subendothelial (between endothelium and GBM): Accessible to circulating inflammatory cells → proliferative response, low complement, active nephritic picture. Seen in lupus Class III/IV, MPGN.
• Subepithelial (between GBM and podocyte): Less accessible to inflammation → more indolent, nephrotic predominant. Seen in membranous nephropathy, lupus Class V.
• Mesangial: Complexes trapped by mesangial cells → mesangial proliferation. Seen in IgA nephropathy, early lupus.
No significant immunoglobulin deposition on IF—injury is mediated by cell-mediated immunity, typically neutrophils activated by ANCA (anti-neutrophil cytoplasmic antibodies).
Diseases: Granulomatosis with polyangiitis (GPA, c-ANCA/PR3), microscopic polyangiitis (MPA, p-ANCA/MPO), eosinophilic granulomatosis with polyangiitis (EGPA).
Mechanism: ANCA activates neutrophils → neutrophils adhere to endothelium → degranulation releases proteases and ROS → necrotizing injury → crescent formation. This is RPGN—rapidly progressive glomerulonephritis with crescent formation.
Why Nephritic Syndrome Looks the Way It Does
Why does glomerular inflammation cause hematuria?
Inflammation damages the GBM and endothelium, creating actual breaks in the barrier. Inflammatory mediators (complement, cytokines) increase endothelial permeability. Neutrophil proteases (elastase, cathepsins) directly degrade basement membrane. RBCs squeeze through these gaps into Bowman's space.
Why are RBC casts pathognomonic of glomerular bleeding?
RBCs entering Bowman's space travel down the tubule. In the concentrated, acidic environment of the distal tubule/collecting duct, RBCs become trapped in Tamm-Horsfall protein (uromodulin) and form casts. Casts prove the blood originated in the glomerulus/tubule—lower tract bleeding doesn't form casts. Dysmorphic RBCs (distorted by passing through gaps) further confirm glomerular origin.
Why does nephritic syndrome cause decreased GFR (azotemia)?
Multiple mechanisms: (1) Inflammation and proliferation compress capillary lumens, reducing filtration surface area. (2) Crescents (if present) compress the glomerular tuft. (3) Tubular obstruction by RBC casts. (4) Afferent arteriole vasoconstriction as a response to tubuloglomerular feedback (macula densa senses reduced delivery due to decreased filtration). The net result: ↓GFR, ↑creatinine, oliguria.
Why do patients develop hypertension?
↓GFR means ↓filtered sodium load, but tubular reabsorption continues → net sodium retention → volume expansion → hypertension. Additionally, renal ischemia activates RAAS. Unlike nephrotic syndrome where RAAS activation compensates for intravascular depletion, in nephritic syndrome it adds to already-expanded volume.
Why is proteinuria present but not massive in nephritic syndrome?
The podocyte is not the primary target—inflammation affects endothelium and GBM. However, inflammatory mediators do cause some podocyte injury (bystander effect), and breaks in the GBM allow some protein passage. Typically proteinuria is 1-3 g/day, not the >3.5 g/day of nephrotic syndrome. If proteinuria is nephrotic-range, suspect a mixed picture.
Crescents: The Histological Emergency
Crescents are accumulations of cells in Bowman's space that compress the glomerular tuft. They represent severe injury and predict rapid progression to ESRD if untreated. Crescentic GN is a medical emergency.
Crescent Formation: Step by Step
Step 1 - Barrier Breach: Severe inflammation creates breaks in GBM and Bowman's capsule.
Step 2 - Fibrin Leak: Plasma proteins, especially fibrinogen, leak into Bowman's space. Fibrinogen converts to fibrin.
Step 3 - Cell Influx: Monocytes and macrophages migrate through the breaks, attracted by fibrin and chemokines.
Step 4 - Parietal Cell Proliferation: The parietal epithelial cells of Bowman's capsule proliferate in response to injury.
Step 5 - Crescent Formation: The mixture of inflammatory cells, proliferating parietal cells, and fibrin forms a "crescent" that compresses the glomerular tuft.
Step 6 - Scarring: Over time, cellular crescents become fibrous crescents—irreversible scarring. This is why early aggressive treatment is critical.
Clinical Urgency
RPGN (rapidly progressive GN) is defined by >50% crescents on biopsy and rapid decline in GFR over days to weeks. Causes: Anti-GBM disease, ANCA vasculitis, severe lupus nephritis, severe post-infectious GN. Treatment: High-dose steroids, often plasmapheresis (especially for anti-GBM and severe ANCA), cyclophosphamide or rituximab. Delay = irreversible ESRD.
Post-Streptococcal GN: The Prototype of Immune Complex Disease
Post-streptococcal GN (PSGN) is the classic teaching example of nephritic syndrome. Understanding its mechanism illuminates immune complex disease in general.
Streptococcal Infection (1-3 weeks prior)
Group A β-hemolytic streptococcus (GAS) causes pharyngitis or skin infection (impetigo). Only certain "nephritogenic" strains cause PSGN—strains expressing antigens that trigger pathogenic immune response.
Immune Response to Streptococcal Antigens
The body mounts antibody response against streptococcal antigens (streptolysin O, DNase B, nephritis-associated plasmin receptor/NAPlr). This is a normal, appropriate immune response.
Immune Complex Formation
Antibody-antigen complexes form in circulation OR streptococcal antigens "plant" in the glomerulus first, then antibodies bind in situ. Either way, immune complexes end up in the glomerulus—predominantly subepithelial ("humps" visible on EM).
Complement Activation
Immune complexes activate the classical complement pathway. C3 is deposited in glomeruli. C3 is consumed → serum C3 is LOW (important diagnostic finding). C5a attracts neutrophils; MAC (C5b-9) damages cells directly.
Inflammatory Response → Nephritic Syndrome
Neutrophil infiltration, endocapillary proliferation, and GBM damage cause the nephritic picture: hematuria (RBC casts), ↓GFR (oliguria, azotemia), hypertension, mild proteinuria. Edema is due to volume overload from sodium retention, not hypoalbuminemia.
Resolution (Usually)
PSGN is typically self-limited in children. Once streptococcal antigens are cleared, no new immune complexes form. Existing complexes are gradually cleared. GFR normalizes. Hematuria resolves over weeks to months. Adults have higher risk of incomplete recovery.
Diagnostic Pearl: Complement Levels
Low C3 with normal C4 suggests alternative pathway activation (PSGN, MPGN Type II/C3GN).
Low C3 AND low C4 suggests classical pathway (lupus, cryoglobulinemia, endocarditis).
Normal complement with nephritic syndrome: IgA nephropathy, ANCA vasculitis, anti-GBM disease.
Evidence Base
Sethi S, Fervenza FC. Standardized classification and reporting of glomerulonephritis. Nephrol Dial Transplant 2019 • Rodriguez-Iturbe B, Haas M. Post-streptococcal glomerulonephritis. In: Comprehensive Clinical Nephrology 2019 • Couser WG. Pathogenesis and treatment of glomerulonephritis. Kidney Int 2012
Specific Glomerular Diseases: The Why Behind Each Entity
Each glomerular disease has a specific mechanism that determines its presentation, treatment response, and prognosis. Understanding the "why" for each disease enables rational management.
Primary Causes of Nephrotic Syndrome
The Why of MCD
Why is light microscopy normal? The injury is purely functional, not structural. A circulating factor (likely T-cell derived) disrupts podocyte function without killing cells or causing proliferation. Nothing visible on LM.
Why do steroids work so well? Steroids suppress the T-cell response producing the pathogenic factor. When the factor disappears, podocytes recover. Response is typically rapid (days to weeks).
Why is it the most common cause in children? The immature immune system is prone to aberrant T-cell responses. Most pediatric nephrotic syndrome is MCD and most responds to steroids without biopsy.
Why does it relapse? Steroids suppress but don't cure the underlying immune dysregulation. When steroids are tapered, the factor may reappear. Frequent relapsers may need steroid-sparing agents (cyclophosphamide, calcineurin inhibitors, rituximab).
Why is there no hematuria? No inflammation, no GBM damage. The barrier is functionally leaky but structurally intact.
The Why of FSGS
Why "focal" and "segmental"? Not all glomeruli are affected (focal), and within affected glomeruli, only parts show sclerosis (segmental). This is because FSGS represents podocyte loss—the earliest lesions occur where stress is highest (at the tubular pole), and not every glomerulus loses critical podocyte mass simultaneously.
Why does podocyte loss cause sclerosis? When podocytes detach or die, bare GBM is exposed. Plasma proteins leak into the space, parietal epithelial cells adhere to the bare GBM, and fibrosis/sclerosis ensues. This is irreversible.
Why is FSGS heterogeneous? FSGS is a pattern, not a single disease. Causes include:
• Primary (circulating permeability factor)
• Genetic (mutations in slit diaphragm proteins)
• Adaptive (from nephron loss, obesity, hyperfiltration)
• Virus-associated (HIV, parvovirus B19)
• Drug-associated (heroin, interferon, lithium)
Why is it often steroid-resistant? If cause is genetic or adaptive, steroids cannot help. Even primary FSGS has lower response rates than MCD because actual podocyte loss has occurred.
Why does it recur in transplants? Primary FSGS (with circulating factor) recurs in 30-40% of transplants, often within hours, confirming the systemic humoral factor. Plasmapheresis may help.
The Why of Membranous Nephropathy
Why does the GBM thicken? Immune complexes deposit in the subepithelial space (between GBM and podocyte). The podocyte responds by laying down new basement membrane material around the deposits. Over time, the GBM incorporates these deposits and thickens.
Why is it an autoimmune disease? In ~70-80% of primary cases, autoantibodies target PLA2R (phospholipase A2 receptor) on podocytes. In ~15-20%, the target is THSD7A. These are podocyte-specific antigens—antibodies bind in situ forming immune complexes.
Why is there no inflammation despite immune complexes? Subepithelial deposits are on the "wrong side" of the GBM—away from circulating inflammatory cells. Complement is activated but causes podocyte injury (sublytic C5b-9 attack) rather than inflammatory cell recruitment.
Why check for secondary causes? 20-25% of membranous is secondary to malignancy (especially lung, colon, prostate), infections (hepatitis B/C), drugs (NSAIDs, gold), or autoimmune disease (lupus). Malignancy screening is essential in older patients.
Why does it have the highest thrombosis risk? Membranous causes persistent, severe hypoalbuminemia. Additionally, some propose that anti-PLA2R antibodies may have direct prothrombotic effects.
Primary Causes of Nephritic Syndrome
The Why of IgA Nephropathy
Why is it the most common GN worldwide? IgA is the most abundant antibody in mucosal secretions. Any defect in IgA handling can lead to deposition. The prevalence may also reflect increased detection through universal urinalysis screening in some countries.
Why does IgA deposit in glomeruli? Patients produce galactose-deficient IgA1 (Gd-IgA1). This abnormal IgA is recognized by anti-glycan antibodies, forming immune complexes. These complexes have affinity for the mesangium, where they deposit and trigger inflammation.
Why does it present with gross hematuria during infections? "Synpharyngitic" hematuria—gross hematuria occurring within 1-2 days of upper respiratory infection. Mucosal infection stimulates IgA production → more circulating Gd-IgA1 → more immune complex deposition → flare of glomerular inflammation. This is different from PSGN's 1-3 week latency.
Why is the course so variable? IgA nephropathy ranges from benign (microscopic hematuria for decades) to rapidly progressive (crescentic). Prognosis depends on degree of proteinuria, hypertension, GFR at presentation, and histological features (MEST-C score).
Why is complement C3 often normal? IgA activates complement via the alternative and lectin pathways, not classical. This may produce less dramatic C3 consumption than classical pathway activation.
The Why of ANCA Vasculitis
Why do ANCAs cause disease? ANCAs (anti-neutrophil cytoplasmic antibodies) target proteins in neutrophil granules: PR3 (proteinase 3, c-ANCA) or MPO (myeloperoxidase, p-ANCA). When primed by infection or cytokines, neutrophils express these antigens on their surface. ANCA binding activates neutrophils → degranulation → endothelial injury.
Why is immunofluorescence "pauci-immune"? The injury is cell-mediated (neutrophils), not antibody-mediated at the tissue level. ANCAs cause neutrophil activation but don't deposit in the glomerulus themselves. Hence no immunoglobulin staining on IF.
Why are crescents so common? ANCA vasculitis causes necrotizing injury—severe damage to GBM and Bowman's capsule. Fibrin extravasation and inflammatory cell influx lead to crescent formation. ANCA GN is a classic cause of RPGN.
Why are systemic symptoms common? ANCA vasculitis is a systemic disease affecting small vessels throughout the body. GPA: upper/lower respiratory tract + kidneys (sinusitis, pulmonary nodules, GN). MPA: kidneys + lungs (pulmonary capillaritis). EGPA: asthma + eosinophilia + vasculitis.
Why is rituximab effective? Rituximab depletes B cells, reducing ANCA production. Non-inferior to cyclophosphamide for induction; superior for relapsing disease. Remission maintenance typically with low-dose rituximab or azathioprine.
The Why of Anti-GBM Disease
Why does it target both kidneys and lungs? The autoantibodies target the NC1 domain of the α3 chain of type IV collagen, present in GBM and alveolar basement membrane. When alveolar membrane is injured (smoking, infection, inhaled toxins), the antigen becomes accessible → pulmonary hemorrhage. Pulmonary involvement occurs in ~60-70%.
Why is linear IF staining characteristic? The antigen (collagen IV) is distributed uniformly along the entire GBM. Antibodies bind evenly → smooth linear staining, unlike the patchy granular pattern of immune complex disease.
Why is it so aggressive? Direct antibody attack on structural GBM protein causes rapid destruction. Crescentic GN develops quickly. Without treatment (plasmapheresis + immunosuppression), ESRD occurs within weeks.
Why is plasmapheresis essential? Plasmapheresis removes circulating anti-GBM antibodies. Immunosuppression (steroids + cyclophosphamide) prevents new antibody formation. Both are needed—pheresis alone doesn't stop production; immunosuppression alone doesn't remove existing antibodies fast enough.
Why does creatinine at presentation predict outcome? High creatinine (>5-6 mg/dL) or dialysis-dependence at presentation indicates extensive irreversible damage. These patients rarely recover kidney function even with treatment. Early diagnosis is critical.
Diseases with Features of Both Syndromes
The Why of Lupus Nephritis
Why can lupus present as either syndrome? Lupus nephritis has 6 ISN/RPS classes based on location and extent of immune complex deposition:
• Class I/II: Mesangial—mild, often asymptomatic
• Class III: Focal proliferative—nephritic features
• Class IV: Diffuse proliferative—severe nephritic, worst prognosis
• Class V: Membranous—nephrotic features
• Class VI: Sclerotic—end-stage
Patients can present with pure nephrotic (Class V), pure nephritic (Class III/IV), or mixed. Class can change over time.
Why is complement low in active lupus? Lupus activates classical complement pathway via immune complexes containing dsDNA antibodies. C3 AND C4 are consumed. Low complement suggests active disease; rising levels suggest response to treatment.
Why is lupus nephritis treated with intensive immunosuppression? Class III/IV lupus nephritis is a major driver of morbidity and mortality. Induction with mycophenolate or cyclophosphamide + steroids; maintenance with mycophenolate or azathioprine. Newer agents include voclosporin, belimumab added to standard therapy.
The Why of MPGN
Why the dual name pattern? "Membranoproliferative" describes two findings: GBM thickening/duplication ("membrano") + mesangial proliferation ("proliferative"). The GBM thickens because new basement membrane is laid down around subendothelial deposits, creating the characteristic "tram-track" appearance.
Why reclassify by immunofluorescence? MPGN is now classified by IF findings:
• Immune complex MPGN (Ig-positive): Secondary to hepatitis C, autoimmune disease, monoclonal gammopathy
• Complement-mediated (C3-dominant): Due to complement dysregulation (C3 glomerulopathy)
Why does hepatitis C cause MPGN? HCV leads to cryoglobulinemia—cold-precipitating immunoglobulins that deposit in glomeruli. These activate complement and cause the MPGN pattern. Treatment is antiviral therapy to clear HCV.
Why is it nephrotic AND nephritic? Subendothelial deposits cause inflammation (nephritic features) while podocyte injury from complement attack causes heavy proteinuria (nephrotic features). The combination yields the classic "mixed" picture with active sediment AND nephrotic-range proteinuria.
Evidence Base
KDIGO 2021 Clinical Practice Guideline for Glomerulonephritis • Bomback AS, Appel GB. Updates on the Treatment of Lupus Nephritis. JASN 2010 • Couser WG. Primary membranous nephropathy. CJASN 2017 • Cattran DC, Feehally J. Kidney Disease: Improving Global Outcomes (KDIGO) GN Work Group. Kidney Int Suppl 2021
Complications: Understanding Why They Occur
Glomerular diseases cause complications beyond the kidneys themselves. Understanding the pathophysiology of complications enables prevention and targeted treatment.
Complications of Massive Protein Loss
Loss of Immunoglobulins: IgG (~150 kDa) is filtered through the damaged glomerulus. IgG levels fall significantly, impairing opsonization and complement-mediated killing.
Loss of Complement Factors: Factor B and Factor D are lost in urine, impairing alternative complement pathway.
Classic Infection: Spontaneous bacterial peritonitis (SBP) with Streptococcus pneumoniae. Pneumococcal vaccination is essential.
Loss of Anticoagulants: Antithrombin III (~58 kDa) and protein S are lost in urine.
Increased Procoagulants: Liver increases synthesis of fibrinogen, factors V, VII, VIII.
Sites of Thrombosis: DVT/PE most common. Renal vein thrombosis especially in membranous nephropathy.
Prevention: Consider prophylactic anticoagulation when albumin <2.0-2.5 g/dL.
Mechanism: Low oncotic pressure stimulates hepatic lipoprotein synthesis. Lipoprotein lipase activity is reduced.
Long-term Risk: Chronic nephrotic syndrome accelerates atherosclerosis.
Treatment: Statins indicated for persistent hyperlipidemia.
Complications of Glomerular Inflammation
Mechanism: Acute ↓GFR → inability to excrete sodium → volume expansion → severe hypertension.
Complications: Hypertensive encephalopathy, pulmonary edema, retinopathy.
Management: Loop diuretics, antihypertensives. Dialysis if refractory.
Mechanism: Volume overload from sodium retention causing intravascular expansion.
Differentiation: Must distinguish from DAH in ANCA vasculitis or Goodpasture.
Treatment: Diuresis for volume overload; immunosuppression for DAH.
Progression to CKD: The Final Common Pathway
Why does glomerular disease lead to tubulointerstitial fibrosis?
Proteinuria is directly toxic to tubular epithelial cells. Filtered proteins trigger inflammatory pathways, oxidative stress, and TGF-β release, leading to scarring.
Why is proteinuria the best predictor of progression?
Because proteinuria directly drives tubulointerstitial damage. Higher proteinuria = more tubular injury = faster progression. Reducing proteinuria slows CKD progression.
Why do ACE inhibitors/ARBs slow progression beyond BP control?
They dilate the efferent arteriole → ↓intraglomerular pressure → ↓protein filtration → less tubular toxicity. This is why ACEi/ARBs are first-line for all proteinuric CKD.
Why are SGLT2 inhibitors nephroprotective?
They restore tubuloglomerular feedback and cause afferent arteriolar constriction → ↓intraglomerular pressure. DAPA-CKD and EMPA-KIDNEY trials showed benefit regardless of diabetes.
Why do some glomerular diseases recur after transplant?
If the underlying cause is systemic (circulating factor in FSGS, anti-PLA2R in membranous), the new kidney is exposed to the same mechanism. Recurrence: FSGS ~30-40%, membranous ~30-40%.
The Pillars of CKD Progression Prevention
1. Control blood pressure (<130/80 in proteinuric CKD)
2. Maximize RAAS blockade (ACEi or ARB)
3. Add SGLT2 inhibitor (if eGFR ≥20)
4. Treat underlying disease
5. Avoid nephrotoxins (NSAIDs, contrast)
Evidence Base
KDIGO 2024 CKD Guidelines • Heerspink HJL, et al. DAPA-CKD Trial. NEJM 2020 • EMPA-KIDNEY Collaborative Group. NEJM 2023 • Ruggenenti P, et al. Proteinuria predicts ESRF. Kidney Int 1998
Clinical Integration: From Mechanism to Management
Understanding the "why" transforms clinical decision-making. This section integrates pathophysiology with practical diagnosis and treatment.
The Systematic Evaluation of Glomerular Disease
Recognize Glomerular Disease
Key findings: Proteinuria (especially >500 mg/day), hematuria with dysmorphic RBCs or RBC casts, hypoalbuminemia, edema. Proteinuria + hematuria together strongly suggests glomerular origin. Isolated hematuria without proteinuria is less likely glomerular.
Classify as Nephrotic vs. Nephritic
Nephrotic: Proteinuria >3.5 g/day, hypoalbuminemia, edema, hyperlipidemia, minimal hematuria.
Nephritic: Active sediment (RBC casts), hypertension, ↓GFR, oliguria, mild-moderate proteinuria.
Mixed: Features of both—heavy proteinuria WITH active sediment (think MPGN, lupus).
Serological Workup
All patients: CBC, CMP, albumin, lipids, urinalysis with microscopy, spot urine protein/creatinine ratio, hepatitis B/C, HIV, ANA.
Nephritic features: Add C3/C4, ANCA, anti-GBM, ASO/anti-DNase B (if post-infectious suspected).
Nephrotic (adult): Add SPEP/UPEP (rule out amyloid/myeloma), anti-PLA2R (if membranous suspected), age-appropriate malignancy screening.
Determine Need for Biopsy
Biopsy indicated: Adults with nephrotic syndrome (except clear diabetic nephropathy), unexplained AKI with glomerular features, RPGN, suspected vasculitis or lupus nephritis, steroid-resistant nephrotic syndrome.
Biopsy may be deferred: Children with first episode of nephrotic syndrome (treat empirically for MCD), classic post-streptococcal GN with expected recovery.
Interpret Biopsy: The Three Tools
Light Microscopy: Pattern of injury (proliferative, sclerotic, crescentic, membranous thickening).
Immunofluorescence: What's deposited (IgG, IgA, IgM, C3, C1q) and pattern (linear, granular, mesangial).
Electron Microscopy: Location of deposits (subepithelial, subendothelial, mesangial), foot process effacement, GBM abnormalities.
Pattern Recognition: Putting It Together
Case Pattern: Child with Periorbital Edema, 4+ Proteinuria, Bland Sediment
Syndrome: Nephrotic
Most likely diagnosis: Minimal Change Disease (most common cause of childhood nephrotic syndrome)
Why? Periorbital edema (dependent edema in children who lie flat), massive proteinuria without hematuria (podocyte injury, intact GBM), no systemic symptoms.
Management: Empiric prednisone without biopsy. ~90% will respond within 4 weeks. Reserve biopsy for steroid resistance or atypical features.
Case Pattern: Adult with Edema, Proteinuria 8g/day, Normal Creatinine, History of DVT
Syndrome: Nephrotic
Most likely diagnosis: Membranous Nephropathy
Why? Adult-onset nephrotic syndrome with thrombosis (highest VTE risk in membranous), preserved GFR early.
Workup: Anti-PLA2R antibody (positive in 70-80% primary), biopsy for confirmation, malignancy screening (especially >65 years), hepatitis B serology.
Management: ACEi/ARB, anticoagulation (given VTE history), consider immunosuppression if persistent nephrotic-range proteinuria and declining GFR (rituximab or calcineurin inhibitor-based regimen).
Case Pattern: Teen with Gross Hematuria 2 Days After URI
Syndrome: Nephritic
Most likely diagnosis: IgA Nephropathy
Why? Synpharyngitic timing (hematuria within days of infection, not weeks). IgA production increases with mucosal infection → immediate flare.
Distinguish from PSGN: PSGN has 1-3 week latency, low C3, positive strep serologies. IgA has immediate timing, usually normal C3.
Workup: Urinalysis (RBC casts confirm glomerular origin), creatinine, C3/C4 (usually normal in IgA), biopsy if persistent proteinuria/hematuria or elevated creatinine.
Case Pattern: 60yo with RPGN, Hemoptysis, p-ANCA Positive
Syndrome: Nephritic (RPGN)
Most likely diagnosis: Microscopic Polyangiitis (MPA)
Why? Pulmonary-renal syndrome (hemoptysis + GN), p-ANCA/MPO positive, rapid GFR decline. This is pauci-immune crescentic GN.
Urgency: RPGN is a medical emergency. Start empiric methylprednisolone pulses while awaiting biopsy confirmation. Consider plasmapheresis if severe (DAH, dialysis-dependent).
Treatment: Induction with rituximab or cyclophosphamide + steroids. Maintenance with rituximab or azathioprine.
Case Pattern: Young Woman with Proteinuria, Hematuria, Low C3 & C4, ANA Positive
Syndrome: Mixed (nephrotic + nephritic features)
Most likely diagnosis: Lupus Nephritis
Why? Young woman (SLE demographics), active sediment + proteinuria (suggests proliferative class), low C3 AND C4 (classical pathway from immune complexes), positive ANA.
Workup: Anti-dsDNA, anti-Smith, complete lupus serologies. Kidney biopsy essential to classify (treatment depends on class).
Treatment: Class III/IV: Induction with mycophenolate or cyclophosphamide + steroids; maintenance with mycophenolate. Consider adding voclosporin or belimumab per recent trials.
Mechanism-Based Therapy
Supportive (All patients):
• ACEi/ARB: Reduce intraglomerular pressure, ↓proteinuria
• SGLT2 inhibitor: Additional antiproteinuric effect
• Sodium restriction: <2g/day to control edema
• Diuretics: Loop + thiazide for refractory edema
• Statin: For persistent hyperlipidemia
• VTE prophylaxis: If albumin <2-2.5 g/dL
Disease-Specific:
• MCD: Prednisone (excellent response)
• FSGS: Steroids ± CNI, rituximab if resistant
• Membranous: Rituximab or CNI-based regimen
Supportive (All patients):
• Blood pressure control: Target <130/80
• Volume management: Diuretics, sodium restriction
• ACEi/ARB: When stable (avoid in acute AKI)
• Dialysis: If uremia, refractory hyperkalemia/volume
Disease-Specific:
• Post-infectious GN: Supportive (usually self-limited)
• IgA Nephropathy: RAAS blockade; steroids if high risk
• ANCA vasculitis: Rituximab or CYC + steroids
• Anti-GBM: Plasmapheresis + CYC + steroids
• Lupus Class III/IV: MMF or CYC + steroids
— The Principle of Glomerular Medicine
Key References
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases • Kidney Int 2021 • Rovin BH, et al. KDIGO 2024 Lupus Nephritis Guidelines • Floege J, Feehally J. Introduction to glomerular disease: clinical presentations. Comprehensive Clinical Nephrology 7th ed • MENTOR Trial (Rituximab in Membranous). NEJM 2019 • TESTING Trial (Steroids in IgAN). JAMA 2022